Further evidence of Saa’s involvement in NAFLD progression comes from studies in hypercholesterolemic mice lacking IL-1α or IL-1β, which are key cytokines required for the transition from steatosis to NASH and fibrosis [148]. The gene discussed is SAA2; the disease is metabolic dysfunction-associated steatohepatitis.